VistaGen Therapeutics Inc. Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

VistaGen VTGN, a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous systems (“CNS”) disorders, today announced the initiation of a phase 2A clinical trial to evaluate the efficacy, safety, and tolerability of PH94B as a potential treatment of anxiety in adults with adjustment disorder with anxiety (“AjDA”). In parallel with advancing its ongoing PALISADE phase 3 clinical program for PH94B in the acute treatment of anxiety in adults with a social anxiety disorder (“SAD”), VistaGen plans to explore PH94B’s potential in additional anxiety disorders through a series of small phase 2A trials, the first of which is in AjDA.

“As we continue to advance ongoing phase 3 clinical development of PH94B in our PALISADE phase 3 program in social anxiety disorder, we are excited to launch our phase 2A clinical program to explore PH94B’s potential in multiple additional anxiety disorders with unmet need,” said Shawn Singh, chief executive officer of VistaGen. “There has been a significant shift in mental health since early last year. Emotional stress and impaired functioning as a result of anxiety-provoking stressors brought on by sudden changes in health, safety, economic and social circumstances, including the diverse impacts of the COVID-19 pandemic, have directly or indirectly affected hundreds of millions of individuals around the world and may have led to a considerable increase in the prevalence of adjustment disorder with anxiety. We believe the impact of the pandemic on mental health will be long-term and varied across a wide range of anxiety disorders, and we are committed to becoming part of the solution for people who need to find help. Expanding on our ongoing efforts to address the alarming prevalence of social anxiety disorder, the initiation of this exploratory phase 2A study in adjustment disorder with anxiety is an exciting next step toward our goal.”

To view the full press release, visit https://ibn.fm/fGyZc

About VistaGen Therapeutics Inc.

VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn, Instagram and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Image Sourced from Pixabay

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.